| __timestamp | BioMarin Pharmaceutical Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 396000000 |
| Thursday, January 1, 2015 | 634806000 | 364000000 |
| Friday, January 1, 2016 | 661905000 | 376000000 |
| Sunday, January 1, 2017 | 610753000 | 382000000 |
| Monday, January 1, 2018 | 696328000 | 432000000 |
| Tuesday, January 1, 2019 | 715007000 | 457000000 |
| Wednesday, January 1, 2020 | 628116000 | 463000000 |
| Friday, January 1, 2021 | 628793000 | 508000000 |
| Saturday, January 1, 2022 | 649606000 | 539000000 |
| Sunday, January 1, 2023 | 746773000 | 614000000 |
| Monday, January 1, 2024 | 747184000 | 686000000 |
Infusing magic into the data realm
In the ever-evolving landscape of pharmaceuticals, innovation is the lifeblood of progress. Over the past decade, BioMarin Pharmaceutical Inc. and Zoetis Inc. have demonstrated a steadfast commitment to research and development (R&D), a critical driver of their success. From 2014 to 2023, BioMarin's R&D expenses surged by approximately 62%, reflecting their dedication to pioneering treatments. Meanwhile, Zoetis, a leader in animal health, increased its R&D spending by nearly 55%, underscoring its focus on advancing veterinary medicine.
BioMarin consistently outpaced Zoetis in R&D investment, with 2023 marking a peak of $747 million. Zoetis, however, showed remarkable growth, reaching $614 million in the same year. This trend highlights the dynamic nature of the pharmaceutical industry, where strategic investments in innovation can lead to groundbreaking advancements and sustained growth.
Explore the chart to see how these companies have prioritized innovation over the years.
Research and Development: Comparing Key Metrics for Zoetis Inc. and Viatris Inc.
Zoetis Inc. vs BioMarin Pharmaceutical Inc.: A Gross Profit Performance Breakdown
Research and Development Expenses Breakdown: Zoetis Inc. vs Xenon Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Zoetis Inc. vs MorphoSys AG
Research and Development: Comparing Key Metrics for Zoetis Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs BioMarin Pharmaceutical Inc.
R&D Insights: How Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc. Allocate Funds
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
R&D Insights: How BioMarin Pharmaceutical Inc. and Supernus Pharmaceuticals, Inc. Allocate Funds
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs MannKind Corporation: Strategic Focus on R&D Spending